DSMB backs Athenex's Phase III breast cancer trial of Oraxol

Athenex Inc. (NASDAQ:ATNX) said an independent DSMB recommended continuation of the Phase III Oraxol 001 trial of Oraxol to treat metastatic breast cancer based on interim safety and overall response rate (ORR) data.

The open-label, international trial is enrolling 360 patients to receive oral Oraxol or IV paclitaxel. The study's primary endpoints are safety and tumor response. Secondary endpoints include progression-free survival (PFS) and overall survival (OS)...